Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 03, 2015 1:41 PM ET


Company Overview of Receptos, Inc.

Company Overview

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical st...

3033 Science Park Road

Suite 300

San Diego, CA 92121

United States

Founded in 2008

68 Employees





Key Executives for Receptos, Inc.

Chief Executive Officer, President and Director
Age: 57
Total Annual Compensation: $534.4K
Co-Founder and Chief Technology Officer
Age: 55
Total Annual Compensation: $317.0K
Co-Founder and Chief Scientific Officer
Age: 59
Total Annual Compensation: $317.0K
Chief Financial Officer
Age: 45
Total Annual Compensation: $386.8K
Chief Medical officer
Age: 45
Total Annual Compensation: $437.8K
Compensation as of Fiscal Year 2014.

Receptos, Inc. Key Developments

Receptos, Inc.(NasdaqGS:RCPT) added to Russell 1000 Index

Receptos, Inc. has been added to Russell 1000 Index.

Receptos, Inc.(NasdaqGS:RCPT) dropped from Russell 2000 Index

Receptos, Inc. will be removed from Russell 2000 Index

Receptos Reportedly Rejects Takeover Bids

Receptos, Inc. (NasdaqGS:RCPT) has rejected takeover offers from AstraZeneca PLC (LSE:AZN), Gilead Sciences Inc. (NasdaqGS:GILD) and Teva Pharmaceutical Industries Limited (NYSE:TEVA), according to sources. AstraZeneca offered $200 per share while Gilead and Teva offered $280 per share, sources reported. Receptos reportedly rejected offers claiming they undervalued it.

Similar Private Companies By Industry

Company Name Region
Partikula LLC United States
Genovel Orthopedics, Inc. United States
OnKure, Inc. United States
Miltenyi Biotec Inc. United States
GenoRx, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Receptos, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at